Stansberry Research

This Drugmaker Will Survive Its 'Patent Cliff'

Dr. David EifrigRetirement Trader
In today's issue of Retirement Trader, editor Dr. David Eifrig recommends a company that's a perfect opportunity to sell options. Investors have priced in a likely revenue loss, but we're optimistic about its future...

To read the full story

Not ready to subscribe? Subscribe above to receive all of Stansberry Research's free newsletters directly in your inbox.